Açaí (Euterpe oleracea Mart.) beverage consumption improves biomarkers for inflammation but not glucose- or lipid-metabolism in individuals with metabolic syndrome in a randomized, double-blinded, placebo-controlled clinical trial

Food & Function
Hyemee KimSusanne U Mertens-Talcott

Abstract

Açaí (Euterpe oleracea Mart.) berries, characterized by high polyphenol concentrations (predominantly anthocyanins), have demonstrated anti-inflammatory and anti-diabetic activities. The study objective was to determine the modulation of lipid and glucose-metabolism, as well as oxidative stress and inflammation, by an açaí-beverage (containing 1139 mg L-1 gallic acid equivalents of total polyphenolics) in 37 individuals with metabolic syndrome (BMI 33.5 ± 6.7 kg m-2) who were randomized to consume 325 mL twice per d of a placebo control or açaí-beverage for 12 weeks. Anthropometric measurements, dietary intake, and blood and urine samples were collected at baseline and after 12 weeks of consumption. Two functional biomarkers, plasma level of interferon gamma (IFN-γ) and urinary level of 8-isoprostane, were significantly decreased after 12 weeks of açaí consumption compared to the placebo control (p = 0.0141 and 0.0099, respectively). No significant modification of biomarkers for lipid- and glucose-metabolism was observed in this study. Findings from this small pilot study provide a weak indication that the selected dose of açaí polyphenols may be beneficial in metabolic syndrome as only two biomarkers for inflammation and oxida...Continue Reading

References

Jun 29, 2004·Behavioural Brain Research·Jill M TallSrinivasa N Raja
Oct 26, 2006·Journal of Agricultural and Food Chemistry·Alexander G SchaussJames P Kababick
Mar 29, 2008·Metabolic Syndrome and Related Disorders·Julie P SutherlandRobert H Eckel
Mar 3, 2009·Journal of the American Dietetic Association·Erica M HoltAlan R Sinaiko
May 2, 2009·Disease Models & Mechanisms·Paul L Huang
Jul 28, 2010·The Journal of Nutrition·Arpita BasuTimothy J Lyons
Aug 28, 2010·Nutrition Research·Arpita BasuTimothy J Lyons
Sep 15, 2010·Journal of Cardiovascular Pharmacology·Paola Raquel Braz de OliveiraAngela Castro Resende
Jul 9, 2011·The British Journal of Nutrition·Indika EdirisingheBritt M Burton-Freeman
Aug 18, 2012·British Journal of Clinical Pharmacology·Maarit J ReinMarcia da Silva Pinto
Jul 16, 2013·The Journal of Nutritional Biochemistry·Fernando CardonaMaría Isabel Queipo-Ortuño
Jan 9, 2014·Journal of Agricultural and Food Chemistry·Debora EspositoMary Ann Lila
Feb 21, 2014·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·A Tresserra-RimbauUNKNOWN PREDIMED Study Investigators
Jun 28, 2017·Molecular Nutrition & Food Research·Janet A NovotnyMario G Ferruzzi

❮ Previous
Next ❯

Citations

Jul 16, 2020·Current Developments in Nutrition·Theresa F RambaranAnna Nordström
Dec 20, 2018·Frontiers in Pharmacology·Rozita NaseriSaeideh Momtaz
Dec 16, 2020·Nutrición hospitalaria·Melina Oliveira de SouzaRenata Nascimento de Freitas
Jul 3, 2021·International Journal of Molecular Sciences·Shiyao ZhangSiyu Chen
Jul 25, 2021·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Aleksandra Kozłowska, Tomasz Dzierżanowski

❮ Previous
Next ❯

Methods Mentioned

BETA
X-ray

Clinical Trials Mentioned

NCT02227628

Software Mentioned

Power
SAS

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here